ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) IN PEDIATRICS

Mr. Qureshi Abdul Mabud, Dr. Dinesh Kumar Jain*

IPS Academy College of Pharmacy, Knowledge Village, Rajendra Nagar, A.B. Road, Indore 452012

Corresponding Author: Dr. Dinesh Kumar Jain

Director

IPS Academy College of Pharmacy, Knowledge Village, Rajendra Nagar,

A.B. Road, Indore 452012

Email: Jaindkj57@yahoo.com

ABSTRACT

Attention Deficit Hyperactivity Disorder (ADHD) is a prevalent neurodevelopmental condition characterized by inattention, hyperactivity, and impulsivity, affecting 5–10% of children globally. This review explores ADHD's epidemiology, including its subtypes (mixed, hyperactive-impulsive, and inattentive) according to the DSM, and its varying prevalence influenced by cultural considerations and diagnostic standars. The etiology of ADHD is multifactorial, involving genetic, neurobiological, and environmental contributors, with neuroimaging studies highlighting structural abnormalities in areas of the brain like the cerebellum and prefrontal cortex. Diagnosis is clinical, relying on standardized criteria and behavioral assessments, often complicated by comorbidities like anxiety, depression, and oppositional defiant disorder. ADHD symptoms, including inhibition deficits and task-related challenges, manifest early and persist across multiple settings. Treatment strategies encompass behavioral interventions, pharmacological options (primarily stimulants like methylphenidate), and adjunct therapies, including non-stimulants and alternative approaches such as herbal remedies. Effective management emphasizes an integrated approach tailored to the individual, involving families, educators, and healthcare providers to enhance results and life quality.

Keywords : *ADHD, Meta Analysis, Stimulants, Non Stimulants, Herbal Remedies.*

1. INTRODUCTION

A neurodevelopmental disorder known as Attention Deficit Hyperactivity Disorder (ADHD) is characterized by impulsivity, hyperactivity, and inattention that are inconsistent with what is expected for a person's developmental stage.[1] Although heritability estimates from twin studies indicate that ADHD has a significant genetic component ranging from 70% to 80% genetics alone do not fully account for the condition.[2]Hyperactivity in children is a frequently encountered issue characterized by excessive energy, impulsive actions, and difficulties with sustained attention. While occasional high-energy behavior is typical for children, hyperactivity becomes problematic when it disrupts daily activities, social interactions, or learning. It is most frequently associated with Attention Deficit Hyperactivity Disorder (ADHD), a neurodevelopmental condition that affects 5–10% of kids globally. Children exhibiting hyperactivity may find it challenging to remain still, concentrate on tasks, or regulate their impulses, leading to difficulties in academic settings, at home, and with peers. Early childhood is usually when symptoms first develop, and they might continue until adolescence and maturity. Although hyperactivity is often rooted in genetic factors, environmental influences, prenatal conditions, and brain development also contribute to its onset. Recognizing hyperactivity in pediatric populations is essential for early diagnosis and effective management. Timely interventions such as behavioral therapy, parenting strategies, and educational adjustments can greatly

enhance outcomes for affected children. Often called hyperkinetic disorder, attention-deficit/hyperactivity disorder (ADHD) is a common condition marked by symptoms of impulsivity, hyperactivity, or inattention. Following the initial identification of ADHD by a German physician in 1775, the amount of research supporting its diagnosis and treatment has grown significantly.[3]

2. OBJECTIVES OF ADDRESSING HYPERACTIVITY IN PEDIATRICS

Fig-1: Objectives of Addressing Hyperactivity

3. Epidemiology

ADHD is a prevalent condition among youth globally. A 2007 meta-analysis, which reviewed over 100 studies, estimated approximately 5.3% of kids and teenagers worldwide suffer with ADHD, with a 95% confidence interval ranging from 5.01% to 5.56%.[3]

Variations in the prevalence of ADHD can be attributed to several factors, including differences in diagnostic and assessment practices, the criteria used to determine the severity of impairment for diagnosis, cultural factors (such as understanding the illness and varying degrees of tolerance for specific actions), and the specific population being studied.[1]

The incidence of ADHD varies significantly, with estimates 2% to 16%, contingent on the diagnostic standards and instruments employed. About 3% to 7% of school-age children meet the criteria for an ADHD diagnosis, under DSM-IV-TR guidelines. Among younger children, compared to the inattentive subtype, the primarily hyperactive/impulsive and mixed subtypes are identified more often. Boys are diagnosed with ADHD more frequently than girls, although the male-to-female ratio varies greatly, ranging from 1:1 in community-based samples to 6:1 in clinical samples. Although there is no racial difference in incidence rates in the US, children of African American and Hispanic descent are less likely to report symptoms of ADHD and seek treatment, irrespective of family financial situation.[4]

ADHD is divided into three different subgroups by the DSM-IV: inattentive, hyperactive-impulsive, and mixed. This classification represents the latest resolution in the ongoing discussion about whether ADHD is best understood as a singular condition or one with multiple dimensions. ADHD is fairly common, with estimates suggesting 2% to 14% of school-age children are affected, depending on the criteria. The behavioral challenges linked to ADHD, both at home and in school, often lead to treatment being sought in primary care settings as well as specialized treatment centers.[5]

Three main subgroups of ADHD are distinguished by the DSM-5 according to the degree of two symptom dimensions: Hyperactivity-impulsivity and inattention. People who exhibit severe inattention without

hyperactivity-impulsivity fall under the first category, mainly inattentive (ADHD-I). People with significant hyperactivity-impulsivity but little inattention are described by the second, predominantly hyperactive-impulsive (ADHD-H) type. Finally, those who demonstrate notable signs of both inattention and hyperactivity-impulsivity are classified as having the combined subtype of ADHD-C. In children and adolescents, the total prevalence of ADHD is 7.2%, with a 95% confidence interval between 6.7% and 7.8%, according to a recent meta-analysis that included 179 prevalence estimates. The most prevalent of the three subtypes of ADHD, according to international scientific research, is the primarily inattentive type (ADHD-I), which is followed by the mixed type (ADHD-C) and the hyperactive-impulsive type (ADHD-HI). The ADHD-I subtype is particularly prevalent among girls compared to other subtypes. Additionally, epidemiological data indicate that across all three subtypes, ADHD diagnoses are more common among boys.[6]

Approximately 5% of children worldwide suffer from Attention Deficit Hyperactivity Disorder (ADHD), one of the most prevalent neurodevelopmental diseases in children, according to the National Institute for Health and Care Excellence. According to estimates, between 10.2% and 10.5% of children in the US have an ADHD diagnosis, and the frequency rises with age. Boys have a higher prevalence of ADHD than girls have (12.7% versus 5.6%, respectively). Children with public health care coverage and those from poorer socioeconomic backgrounds also show greater prevalence rates. ADHD diagnoses often peak in adolescence, where behavioral and academic challenges become more pronounced. Comorbid conditions are common, affecting nearly two-thirds of children with ADHD. These include anxiety disorders, conduct problems, and depression. Despite its prevalence, ADHD often remains underdiagnosed or inadequately treated, particularly in marginalized groups, leading to disparities in access and outcomes. Effective management often combines medication, behavioral therapy, and educational support.[8][9]

Efforts to improve ADHD diagnosis and treatment emphasize a more integrated approach across health, education, and social care systems to address unmet needs and disparities in service provision.[9] The incidence of ADHD is believed to be around 5.3% worldwide, making it one of the most common neurodevelopmental diseases in young people.Compared to prevalence estimates based on research, 10% of youngsters in the US are estimated to have an ADHD diagnosis. This difference is attributed to increased clinical recognition and potential overdiagnosis due to overlapping symptoms with other conditions. ADHD diagnosis is more frequent in boys (over twice as likely as in girls), in children from lower-income families, and among white children compared to nonwhite children. These differences are influenced by diagnostic and cultural biases.[10]

Epidemiologic studies provide only an approximation of clinical diagnostic processes. A critical step in conducting such studies on ADHD is the development of an effective case definition. ADHD, like many other medical and psychiatric conditions, is diagnosed clinically without the support of definitive laboratory tests. Despite being widely utilized in clinical evaluations, instruments such as continuous performance tests—computerized measures of impulsivity and attention—do not have enough sensitivity and specificity.[11]

Researchers have tried to measure behaviors linked to ADHD by methodically observing “off-task” actions or by using devices to measure physical restlessness, such as leg movements. Results from attempts to examine catecholamines or their metabolites in blood or urine have been mixed.[12][13] According to the DSM-IV, there is currently no reliable laboratory test to diagnose ADHD. Because of this, diagnostic methods generally use parent and teacher rating scales or interviews to evaluate a child's conduct throughout the preceding six months. Additionally, it's critical to acknowledge that behavioral and concentration problems may stem from other factors, such as boredom, abuse, or various psychopathological conditions unrelated to ADHD. An extensive history of behavioral symptoms, such as hyperactivity, impulsivity, or inattention, along with proof of the functional impairment these symptoms have produced are necessary for a thorough diagnosis of ADHD.[11]

Co-morbidities, or conditions that co-occur with ADHD, include learning difficulties, conduct disorder, oppositional defiant disorder, Tourette syndrome, depression, anxiety, and bipolar disorder.[14][15] According to estimates, the co-morbidity rates are as follows: roughly 10% for reading difficulties, 27% for anxiety disorders, and 25% to 40% for conduct disorder or oppositional defiant disorder.[16] The prevalence of co-morbid conditions, much like that of ADHD, is highly influenced by methodological differences and definitions. Many of these disorders may present symptoms similar to ADHD, complicating the diagnostic process. Additionally, after receiving an ADHD diagnosis, some diseases may manifest.[11]

4. ETIOLOGY

Although the precise origin of ADHD is yet unknown, early theories linked the condition to diminished brain function, as evidenced by changes in gray and white matter volume or functionality. These alterations were linked

to deficits in motor planning, cognitive processing, attention, response time, and other behavioral issues typical of ADHD. Deficits in particular brain regions, such as the cerebellum, caudate nucleus, and prefrontal cortex (PFC), have been highlighted in more recent studies. The attention, ideas, emotions, behaviors, and actions are all regulated by this integrated brain network. Research on people with ADHD has shown that the PFC, caudate, and cerebellum mature more slowly, have smaller volumes, or are less active. Dopamine (DA) and norepinephrine (NE) are two neurotransmitters that sustain the activity within this network, which is extremely sensitive to its neurochemical environment. These neurotransmitters interact through multiple receptors, both presynaptic and postsynaptic, to support proper functioning.[7]

ADHD may be significantly influenced by neurological and hereditary variables, according to neuroimaging and family studies. Several studies using magnetic resonance imaging (MRI) have found that people with ADHD had smaller volumes or structural abnormalities in particular brain regions when compared to people without the disorder. The frontal lobes, the caudate nucleus, and the globus pallidus are among these areas, which are connected to motor activity, which are crucial for attention; and parts of the corpus callosum. Quantitative MRI analyses indicate that these brain areas are approximately 10% smaller among people with ADHD as opposed to those without.[1]

Around 25% to 33% of biological parents of kids with ADHD are identified by the disorder themselves. Among the genetic correlations found in children with ADHD are the dopamine receptor gene (DRD4) and the dopamine transporter gene (DAT-1). The illness has also been linked to both structural and functional abnormalities in the brain, according to neuroimaging studies. The likelihood of having ADHD has been associated with environmental factors, including exposure to alcohol or cocaine during pregnancy, birth trauma, early childhood exposure to lead, and illnesses like meningitis. Additionally, there has been interest in the potential role of food components, including artificial colors, preservatives, refined sugar, and food allergies, in causing ADHD. However, while most scientific evidence does not support these claims, Certain artificial additives have been found to cause sensitivity in a limited number of children.[4]

5. DIAGNOSIS

ADHD is characterized by two key behavioral dimensions, which encompass the range of symptoms associated with the disorder.[18][19] These characteristics are described in the DSM-IV diagnostic standards, which are the U.S. standard for diagnosis and are being embraced more and more around the world. Research has confirmed the presence of these behavioral dimensions across diverse populations of different ethnicities and cultures.[17]

a) Inattention

The concept of attention is multifaceted and intricate[20][21], making general complaints of inattention insufficient without identifying the specific attention type impacted, for differential diagnosis. ADHD appears to be associated with difficulties in maintaining focus on tasks or activities, adhering to rules and instructions, and resisting distractions during these efforts.[17]

b) Impulsive and Hyperactive Conduct (disinhibition)

Inhibition is a multifaceted concept, much like attention[22][23] , meaning that children may exhibit various distinct types of inhibitory impairments. In ADHD, issues with inhibition primarily involve the executive or voluntary control over dominating reactions, as opposed to impulsive behavior driven by motivational factors such such as excessive anxiety or reward-seeking behavior, which is heightened sensitivity to rewards.[17]

Much like the inattention associated with ADHD, growing evidence indicates that other comorbid psychological diseases do not cause inhibitory impairments.[24-27] These inhibitory challenges typically emerge earlier, around ages 3–4, preceding difficulties with inattention, which appear later, between ages 5–7. The slow cognitive pace that is frequently associated with the mostly inattentive subtype typically appears later, between the ages of 8 and 10.[28-30]

c) Contextual and Situational Considerations

Task-related and situational factors have a major impact on how severe ADHD symptoms are. Children with ADHD typically do worse: (1) later throughout the day as opposed to earlier[31]; (2) when tasks become more complex and require organizational strategies; (3) when a high level of self-restraint is needed[32] ; (4) under

conditions of low stimulation[33] ; (5) when task-related consequences are inconsistent or unpredictable[34] ; (6) during longer delays before rewards are available[35] ; and (7) when adult supervision is absent during tasks.[36]

Beyond task performance, variability in symptom severity is evident across broader settings. Children with ADHD display more behavioral challenges in situations requiring perseverance in tasks relating to the workplace, such housework or homework, or in settings that require self-control, particularly in front of others, like restaurants, churches, or when a parent is on the phone. Interestingly, while these children are more unruly during unstructured play than when their dads are around, their behavior is still rated as less problematic in this scenario than in other contexts.[37]

In school settings, symptom severity fluctuates depending on the environment. Situations requiring focused task completion and behavioral restraint, such as classroom activities, are particularly challenging. Conversely, less structured settings, such as lunch breaks, hallways, or recess, pose fewer difficulties, with the least problems occurring during special events like field trips or assemblies.[38] Four further requirements must be fulfilled in order to receive a full diagnosis of ADHD: signs must appear before the age of seven and be noticeable in a minimum of two distinct environments, including home, school, or the workplace; they should lead to significant impairments impairs social, intellectual, or professional functioning; and they must not just happen in people with psychotic disorders such autism, schizophrenia, or others. Moreover, no other mental health disease, such as a personality disorder, dissociative disorder, anxiety illness, or mood disorder, can adequately explain the symptoms.[39]

The diagnosis of ADHD is made using clinical history and diagnostic criteria, which emphasize the existence of distinctive symptoms that have been present for at least six months and seen in two or more contexts. Clinical interviews with the patient, their parents, or other family members, information collection regarding academic or professional performance, testing for concurrent mental disorders, and a review of medical, social, and family history should all be part of the evaluation process.Each of the 18 symptoms of ADHD described in the DSM-IV must be evaluated by the clinician through a comprehensive interview, with special attention paid to the occurrence, duration, severity, and frequency of each symptom. Along with having the necessary quantity of symptoms, these symptoms must occur consistently, reflecting a stable and chronic pattern rather than oscillating with asymptomatic periods. Symptoms should also have an onset during childhood.It is essential to assess the severity of the impairment and the environments in which it manifests. While the DSM-IV specifies that impairment must be apparent in a minimum of two contexts, such as the workplace, school, or home to fulfill the diagnostic criteria, according to clinical consensus, treatment may still be warranted for severe impairment in a single context.[39]

6. PRESCHOOLERS WITH ADHD

Although school-age children make up the majority of ADHD referrals, early evaluation is essential. It has been noted that preschoolers with ADHD struggle with conduct and social relations, family dynamics, and academics. Both parental and clinical observations highlight a connection between behavioral issues in preschool years and later adjustment difficulties during school age.[40] Children with ADHD may exhibit highly atypical behavior from a very young age, including difficulty concentrating, hyperactivity, restlessness, disobedience, poor social skills, and antisocial tendencies. t is common to witness mothers and their preschool-aged children with ADHD engaging in dysfunctional interactions, which could contribute to the persistence of these disruptive behaviors.[41] Alongside the primary symptoms of ADHD, children with the condition frequently exhibit developmental delays in areas such as sensory processing, motor skills, language development, and intellectual functioning.[42] During the preschool years, kids with ADHD often face multiple challenges, including sensorimotor difficulties. These issues result in a greater need for remedial services including physical, occupational, and speech-language therapy, and they are more likely to be enrolled in special education programs.[43]

According to research, preschoolers with ADHD already exhibit significant challenges in school, social interactions, and overall functioning, comparable to those observed in older kids in school. Nearly 50% of both age groups had mood disorders, with preschoolers having a propensity for greater rates of comorbid bipolar illness.[44] It has been proposed that difficult mother-child relationships and family stress may prevent children from learning healthy coping mechanisms to deal with their early troublesome behaviors., thereby contributing to the persistence of symptoms.[45] Compared to parents of children without ADHD, parents of children with ADHD between the ages of three and five report higher levels of stress, are more likely to have unfavorable interactions with their kids, and use less successful coping mechanisms.[41] t has also been discovered that mothers of preschool-aged children with ADHD have higher levels of despair and a lower feeling of their own responsibilities as parents.[46] It might be difficult to determine the extent of impairment in children ages 2 to 5 because the primary

symptoms of ADHD frequently appear during everyday activities. Furthermore, it is less likely that these actions may be considered developmentally inappropriate.[47][48] Studies indicate that activity level and behaviors like squirming are not reliable traits for distinguishing between preschoolers with and without ADHD.[41]

It is challenging to diagnose ADHD in preschool-aged children, and the reliability of the diagnosis during these formative years has often been questioned.[48][49] It makes sense that there is reluctance to diagnose ADHD in preschoolers due to a lack of developmentally appropriate diagnostic instruments. The most prevalent types are the combination type and hyperactive/impulsive type, however as was previously indicated, children usually do not stay in the hyperactive group as they get older; instead, they frequently go into the combined type.[50] Additionally, due to the fact that ADHD varies in severity throughout age groups, only 48% of children who exhibit severe and frequent enough symptoms to receive an ADHD diagnosis in preschool will continue to have that diagnosis into later childhood or adolescence.[47] However, given the prevalence of hyperactive-impulsive symptoms in preschoolers, early inattentional behavior could be a sign of underlying psychopathology for the aim of early detection.[51]

7. TREATMENT

The first step in any treatment plan for ADHD is to give patients and their families educational materials. Making them aware of national groups like Children and Adults with Attention-Deficit/Hyperactivity Disorder is really important, which offer reliable information on medical, legal, and educational aspects of the condition. Families should be made aware that, although it is frequently, but not always, inherited, ADHD is a neurological illness with no known cause. They should also be reassured that although there isn't a solution, there are efficient ways to assist control the disorder's symptoms.[54]

Medication, psychosocial therapies, or a mix of the two may be used to treat ADHD. Pelham and colleagues' thorough analysis of psychosocial therapies for ADHD[55] highlights at classroom-based behavioral treatments and behavioral parent education—such as "time-out" and point/token incentive systems are well-established approaches. However, cognitive strategies such as self-evaluation, self-monitoring, and self-reinforcement, do not fit the requirements for evidence-based therapies. Psychosocial therapies have significant drawbacks despite their advantages, including being labor-intensive and having effects that are not easily generalized to other environments or behaviors outside the targeted areas.[56]

Results from a number of short-term trials suggest that integrating psychosocial therapies with stimulant medication could make it possible to utilize smaller, possibly safer doses of stimulants.[55] Teachers' and parents' cooperation, motivation, and consistency are critical to the effectiveness of psychosocial therapies. Therapy failures in behavioral interventions are often attributed to improper application of these strategies.[54] Nevertheless, behavioral modification techniques are typically recommended as the primary therapy for children with ADHD who are in preschool.[1]

7.1 Drug-Based Therapy

According to an AAP policy statement from 1996, pharmaceutical treatment for ADHD is suitable when a child or teenager exhibits attention-related symptoms and associated difficulties severe enough to impair learning or the development of interpersonal relationships. The statement emphasizes that medication need to be a component of an all-encompassing strategy rather than the only treatment for ADHD that includes appropriate classroom accommodations, behavior modification, and counselling.[1] In cases of mild to moderate ADHD, behavioral interventions at home and school may be tried before introducing medication. However, in severe cases—such as when impulsive behavior poses a risk to the child—immediate Medical care might be required.[54] In order to address ADHD, the Academy is currently updating its Clinical Practice Guidelines, which will be released shortly.

7.1.1 Stimulants: The most often prescribed drugs for treating ADHD in kids and teenagers are psychostimulants. The United States, roughly 2.8% of school-aged children, or 1.5 million annually, are treated with a stimulant medication.[57] According to a recent study on pediatric prescribing patterns, stimulants are the most commonly given psychotropic medications, with almost 2 million clinic visits and 6 million drug references in 1995.[58] Stimulant drugs have been shown to be effective in all age groups, from young children to adults, although most research data comes from studies involving school-aged children.[59]

In recent years, concerns have emerged about the significant rise in stimulant prescriptions, with some questioning whether These drugs are either overprescribed or maybe abused. However, a recent research conducted by the American Medical Association's Council on Scientific Affairs found little evidence to support claims of common

misinterpretation or overdiagnosis of ADHD, or excessive methylphenidate prescriptions by doctors.[60] Furthermore, results from a community-based study that was carried out as a component of the MECA Study (Methods for the Epidemiology of Child and Adolescent Mental Disorders) indicate that in some parts of the United States, children with ADHD may actually be underprescribed appropriate medication treatments.[61] Despite negative media coverage surrounding stimulant drugs, because of their shown efficacy and safety, they continue to be the first-line pharmaceutical treatment for ADHD. The body of research on treating ADHD with stimulants is extensive, and over 60 years of clinical experience has provided more knowledge about their use in children than any other class of drugs prescribed for the pediatric population.[61]

Many children can benefit from taking pemoline once daily, a long-acting stimulant, but its use is limited because of the possibility of hepatotoxicity.[1 The version of sustained-release of dextroamphetamine (Dexedrine Spansule) can provide more consistent effects.[4] Methylphenidate (e.g., Ritalin, Concerta) is one of the most prescribed treatments, improving symptoms in between 70 and 80 percent of kids with ADHD. Common side effects include appetite suppression and sleep disturbances.[63] Some studies indicate that the steady delivery rate of sustained-release methylphenidate may result in acute tolerance, reducing its effectiveness. The osmotic controlled-release system of extended-release methylphenidate (Concerta) tablets was introduced in response to the need for more reliable once-daily dosing choices. Chewing or crushing these formulations is not recommended; they are meant to be eaten whole.

7.1.2 Non-Stimulants: Although most people benefit with stimulants, others may not react to or cannot tolerate these medications. Although no nonstimulant medications are FDA-approved specifically for ADHD treatment, antidepressants and α2 agonists are among the most researched alternatives. Other drug classes, such as neuroleptics and anticonvulsants, have also been used to manage ADHD symptoms.

1. **Antidepressants:** The most widely used type of antidepressant is tricyclic antidepressant (TCA) medications in this class for treating children with ADHD. They are believed to work by inhibiting the reuptake of specific neurotransmitters, particularly norepinephrine and serotonin. However, their undesirable effects stem from their impact on other neurotransmitter systems, including histaminic, cholinergic, α-adrenergic, and serotonergic pathways.Tricyclic antidepressants (TCAs) are considered second-line treatments for ADHD, typically used for children who do not respond adequately to stimulants or for whom stimulants are contraindicated. Research shows that while TCAs are effective in managing ADHD-related behavioral symptoms, they are generally less effective than stimulants in enhancing attention and concentration.[64] However, TCAs may be particularly beneficial for patients with co-occurring depression, anxiety, or pre-existing tic or Tourette's disorders.[62] Additional advantages of TCAs over stimulants include a longer half-life, which reduces the need for dosing during school hours, fewer disruptions to sleep, appetite, and growth patterns, and a low potential for abuse.[56][62]

   The primary concern with using TCAs in pediatric patients is safety. Cases of sudden, unexplained deaths have been reported with desipramine [65-67] , though the exact cause remains unclear. It is advised to perform an electrocardiogram (ECG) both at baseline and once steady-state levels are reached. Regular monitoring of plasma levels is also recommended. Additionally, the risk of fatality following an overdose is a significant concern, with mortality rates as high as 1% reported for desipramine overdoses.[68] A significant limitation of all TCAs is the high occurrence of adverse effects. These include anticholinergic side effects (such as dry mouth, sedation, weight gain, and constipation), cardiotoxicity, and neurological effects (such as a lowered seizure threshold), which reduce patient acceptance and tolerance of these medications.Other antidepressants have also been explored for treating ADHD. Monoamine oxidase inhibitors (MAOIs), such as tranylcypromine and clorgyline, have demonstrated effectiveness in managing ADHD symptoms. However, due to dietary restrictions and associated risks, MAOIs are rarely used in clinical practice and are generally not recommended for children with ADHD.[68] Selective serotonin reuptake inhibitors (SSRIs) have been less extensively studied in ADHD patients. While an open-label trial of fluoxetine showed promising results [69] , the lack of controlled studies means the role of SSRIs in treating ADHD remains largely preliminary.[68] Nonetheless, SSRIs may serve as a useful adjunct for patients with ADHD who also have comorbid major depressive disorder.[70]

2. **α2 Agonists:** When patients fail to respond to or cannot tolerate first- and second-line treatments, physicians may consider nonstimulant, nonantidepressant options. α2 agonists like clonidine and guanfacine have been studied in ADHD management. Research on clonidine has shown it to be effective in reducing symptoms such as aggression, impulsivity, hyperactivity, and overarousal, although it offers limited improvement in attention and concentration. Common side effects include drowsiness, dizziness, and sedation, while

dysphoria and irritability may also occur. Slower dose titration or dose reduction can help mitigate these adverse effects.[1]

The combination of clonidine and methylphenidate, though controversial, has been explored in open-label trials and used clinically when stimulants alone provide only partial relief or their dosage is restricted due to side effects.[71] However, rare cases of sudden death and cardiac events have been reported with this combination, although no causal link has been conclusively established. Guanfacine is another α2 agonist that has been studied for potential use in ADHD, though it has not been researched as extensively as clonidine. Its advantages include a longer duration of action and fewer sedative side effects compared to clonidine. While open-label studies have shown promising results, no controlled trials have yet been published to assess its efficacy in ADHD.[72][73]

7.2 Other Treatments

I. Behavioral Interventions

1. **Parent Training Programs:**
   - Positive Parenting Program, or Triple P, assists parents in creating consistent routines, reinforce positive behavior, and manage disruptive behavior. Parents are trained in setting clear expectations and implementing time-out strategies.[52]

2. **School-Based Interventions:**
   - Classroom management techniques, such as daily report cards and reward systems, are effective in reducing classroom disruptions and improving focus.[53]

II. Herbal Remedies:

- Extracts like *Bacopa monnieri* (brahmi) have shown potential for reducing hyperactivity and improving attention, but more rigorous trials are needed.[74]

CONCLUSION

ADHD, or attention deficit hyperactivity disorder, is a complicated neurodevelopmental condition with significant implications for pediatric populations, encompassing academic, social, and emotional dimensions. Early recognition and intervention are crucial for mitigating the adverse impacts of hyperactivity and impulsivity, particularly on children's academic success, social integration, and emotional well-being. ADHD's multifactorial etiology, involving genetic, neurobiological, and environmental factors, underscores the importance of a comprehensive diagnostic and treatment approach.While pharmacological treatments, particularly stimulants, remain the cornerstone of ADHD management due to their efficacy, behavioral interventions and psychosocial therapies provide complementary benefits. These approaches empower families, enhance school-based support, and address comorbidities, making treatment plans more holistic. Recent advancements in non-stimulant therapies and alternative remedies offer promising avenues for children who cannot tolerate traditional medications. The document also highlights the ongoing need for an integrated care model, bridging gaps across medical, educational, and social systems to ensure equitable access to diagnosis and treatment. Continued research, particularly on underrepresented groups and emerging therapies, is essential for optimizing outcomes for individuals with ADHD. By fostering collaborative efforts among caregivers, educators, and healthcare providers, we can better assist kids with ADHD in realizing their greatest potential.

REFERENCES

1. Adesman AR. The diagnosis and management of attention-deficit/hyperactivity disorder in pediatric patients. Primary care companion to the Journal of clinical psychiatry. 2001;3(2):66.

2. Otten K, Keller L, Puiu AA, Herpertz-Dahlmann B, Seitz J, Kohn N, Edgar JC, Wagels L, Konrad K. Pre- and postnatal antibiotic exposure and risk of developing attention deficit hyperactivity disorder–A systematic review and meta-analysis combining evidence from human and animal studies. Neuroscience & Biobehavioral Reviews. 2022 Sep 1;140:104776.
3. Faraone SV, Asherson P, Banaschewski T, Biederman J, Buitelaar JK, Ramos-Quiroga JA, et al. Attention-deficit/hyperactivity disorder. Nat Rev Dis Prim. 2015;1(1):15020.
4. Cormier E. Attention deficit/hyperactivity disorder: a review and update. Journal of pediatric nursing. 2008 Oct 1;23(5):345-57.
5. Scahill L, Schwab-Stone M. Epidemiology of ADHD in school-age children. Child and adolescent psychiatric clinics of North America. 2000 Jul 1;9(3):541-55.
6. Ayano G, Yohannes K, Abraha M. Epidemiology of attention–deficit/hyperactivity disorder (ADHD) in children and adolescents in Africa: a systematic review and meta–analysis. Ann Gen Psychiatry [Internet]. 2020;19(21):1-0.
7. Sharma A, Couture J. A review of the pathophysiology, etiology, and treatment of attention-deficit hyperactivity disorder (ADHD). *Ann Pharmacother.* 2014;48(2):209-25.
8. Reuben C, Elgaddal N. Attention-Deficit/Hyperactivity Disorder in Children Ages 5-17 Years: United States, 2020-2022. NCHS Data Brief. No. 499. National Center for Health Statistics. 2024 Mar.
9. Russell S, Hinwood C, Fuller C. Attention deficit hyperactivity disorder (ADHD) Programme update. NHS England; 2024 Mar 28.
10. Peterson BS, Trampush J, Brown M, Maglione M, Bolshakova M, Rozelle M, Miles J, Pakdaman S, Yagyu S, Motala A, Hempel S. Tools for the diagnosis of ADHD in children and adolescents: a systematic review. Pediatrics. 2024 Apr 1;153(4):e2024065854.
11. Rowland AS, Lesesne CA, Abramowitz AJ. The epidemiology of attention-deficit/hyperactivity disorder (ADHD): a public health view. Mental retardation and developmental disabilities research reviews. 2002;8(3):162-70.
12. Halperin JM, Newcorn JH, Schwatrz ST, McKay KE, Bedi G, Sharma V. Plasma catecholamine metabolite levels in ADHD boys with and without reading disabilities. Journal of Clinical Child Psychology. 1993 Jun 1;22(2):219-25.
13. Pliszka SR, Maas JW, Javors MA, Rogeness GA, Baker J. Urinary catecholamines in attention-deficit hyperactivity disorder with and without comorbid anxiety. Journal of the American Academy of Child & Adolescent Psychiatry. 1994 Oct 1;33(8):1165-73.
14. Biederman J, Newcorn J, Sprich S. Comorbidity of attention deficit hyperactivity disorder. Am J Psychiatry. 1991 May;148(5):564-77.
15. Cantwell DP. Attention deficit disorder: a review of the past 10 years. Journal of the American Academy of Child & Adolescent Psychiatry. 1996 Aug 1;35(8):978-87.
16. Szatmari P, Offord DR, Boyle MH. Ontario Child Health Study: prevalence of attention deficit disorder with hyperactivity. Journal of child psychology and psychiatry. 1989 Mar;30(2):219-23.
17. Barkley RA. Issues in the diagnosis of attention-deficit/hyperactivity disorder in children. Brain and development. 2003 Mar 1;25(2):77-83.
18. Lahey BB, Applegate B, McBurnett K, Biederman J, Greenhill L, Hynd GW, Barkley RA, Newcorn J, Jensen P, Richters J. DSM-IV field trials for attention deficit hyperactivity disorder in children and adolescents. The American journal of psychiatry. 1994 Nov 1;151(11):1673-85.
19. DuPaul GJ. Parent and teacher ratings of ADHD symptoms: Psychometric properties in a community-based sample. Journal of Clinical Child and Adolescent Psychology. 1991 Sep 1;20(3):245-53.
20. Bate AJ, Mathias JL, Crawford JR. Performance on the Test of Everyday Attention and standard tests of attention following severe traumatic brain injury. The Clinical Neuropsychologist. 2001 Aug 1;15(3):405-22.
21. Mirsky AF. Disorders of attention: A neuropsychological perspective.
22. Nigg JT. On inhibition/disinhibition in developmental psychopathology: views from cognitive and personality psychology and a working inhibition taxonomy. Psychological bulletin. 2000 Mar;126(2):220. Olson SL, Schilling EM, Bates JE. Measurement of impulsivity: Construct coherence, longitudinal stability, and relationship with externalizing problems in middle childhood and adolescence. Journal of abnormal child psychology. 1999 Apr;27:151-65.
23. Olson SL, Schilling EM, Bates JE. Measurement of impulsivity: Construct coherence, longitudinal stability, and relationship with externalizing problems in middle childhood and adolescence. Journal of abnormal child psychology. 1999 Apr;27:151-65.
24. Barkley RA, Edwards G, Laneri M, Fletcher K, Metevia L. Executive functioning, temporal discounting, and sense of time in adolescents with attention deficit hyperactivity disorder (ADHD) and oppositional defiant disorder (ODD). Journal of abnormal child psychology. 2001 Dec;29:541-56.

25. Murphy KR, Barkley RA, Bush T. Executive functioning and olfactory identification in young adults with attention deficit-hyperactivity disorder. Neuropsychology. 2001 Apr;15(2):211.

26. Nigg JT. The ADHD response-inhibition deficit as measured by the stop task: Replication with DSM–IV combined type, extension, and qualification. Journal of abnormal child psychology. 1999 Oct;27:393-402.

27. Seidman LJ, Biederman J, Faraone SV, Weber W, Ouellette C. Toward defining a neuropsychology of attention deficit-hyperactivity disorder: performance of children and adolescents from a large clinically referred sample. Journal of consulting and clinical psychology. 1997 Feb;65(1):150.

28. Hart EL, Lahey BB, Loeber R, Applegate B, Frick PJ. Developmental change in attention-deficit hyperactivity disorder in boys: a four-year longitudinal study. Journal of abnormal child psychology. 1995 Dec;23:729-49.

29. Loeber R, Green SM, Lahey BB, Christ MA, Frick PJ. Developmental sequences in the age of onset of disruptive child behaviors. Journal of Child and Family Studies. 1992 Mar;1:21-41.

30. Milich R, Balentine AC, Lynam DR. ADHD combined type and ADHD predominantly inattentive type are distinct and unrelated disorders. Clinical psychology: science and practice. 2001;8(4):463.

31. **D**ane AV, Schachar RJ, Tannock R. Does actigraphy differentiate ADHD subtypes in a clinical research setting?. Journal of the American Academy of Child & Adolescent Psychiatry. 2000 Jun 1;39(6):752-60.

32. Luk SL. Direct observation studies of hyperactive behaviors. Journal of the American Academy of Child Psychiatry. 1985 May 1;24(3):338-44.

33. Antrop I, Roeyers H, Van Oost P, Buysse A. Stimulation seeking and hyperactivity in children with ADHD. The Journal of Child Psychology and Psychiatry and Allied Disciplines. 2000 Feb;41(2):225-31.

34. Carlson CL, Mann M. Sluggish cognitive tempo predicts a different pattern of impairment in the attention deficit hyperactivity disorder, predominantly inattentive type. Journal of Clinical Child and Adolescent Psychology. 2002 Feb 2;31(1):123-9.

35. Solanto MV, Abikoff H, Sonuga-Barke E, Schachar R, Logan GD, Wigal T, Hechtman L, Hinshaw S, Turkel E. The ecological validity of delay aversion and response inhibition as measures of impulsivity in AD/HD: a supplement to the NIMH multimodal treatment study of AD/HD. Journal of abnormal child psychology. 2001 Jun;29:215-28.

36. Gomez R, Sanson AV. Mother–child interactions and noncompliance in hyperactive boys with and without conduct problems. Journal of Child Psychology and Psychiatry. 1994 Mar;35(3):477-90.

37. DuPaul GJ, Barkley RA. Situational variability of attention problems: Psychometric properties of the Revised Home and School Situations Questionnaires. Journal of Clinical Child Psychology. 1992 Jun 1;21(2):178-88.

38. Altepeter TS, Breen MJ. Situational variation in problem behavior at home and school in attention deficit disorder with hyperactivity: a factor analytic study. Journal of Child Psychology and Psychiatry. 1992 May;33(4):741-8.

39. Kieling R, Rohde LA. ADHD in children and adults: diagnosis and prognosis. Behavioral neuroscience of attention deficit hyperactivity disorder and its treatment. 2012:1-6.

40. Spira EG, Fischel JE. The impact of preschool inattention, hyperactivity, and impulsivity on social and academic development: A review. Journal of Child Psychology and Psychiatry. 2005 Jul;46(7):755-73.

41. DuPaul GJ, McGoey KE, Eckert TL, VanBrakle J. Preschool children with attention-deficit/hyperactivity disorder: Impairments in behavioral, social, and school functioning. Journal of the American Academy of Child & Adolescent Psychiatry. 2001 May 1;40(5):508-15.

42. Yochman A, Ornoy A, Parush S. Co-occurrence of developmental delays among preschool children with attention-deficit-hyperactivity disorder. Developmental Medicine & Child Neurology. 2006 Jun;48(6):483-8.

43. Marks DJ, Mlodnicka A, Bernstein M, Chacko A, Rose S, Halperin JM. Profiles of service utilization and the resultant economic impact in preschoolers with attention deficit/hyperactivity disorder. Journal of pediatric psychology. 2009 Jul 1;34(6):681-9.

44. Wilens TE, Biederman J, Brown S, Tanguay S, Monuteaux MC, Blake C, Spencer TJ. Psychiatric comorbidity and functioning in clinically referred preschool children and school-age youths with ADHD. Journal of the American Academy of Child & Adolescent Psychiatry. 2002 Mar 1;41(3):262-8.

45. Chi TC, Hinshaw SP. Mother–child relationships of children with ADHD: The role of maternal depressive symptoms and depression-related distortions. Journal of abnormal child psychology. 2002 Aug;30:387-400.

46. Byrne JM, Bawden HN, DeWolfe NA, Beattie TL. Clinical assessment of psychopharmacological treatment of preschoolers with ADHD. Journal of Clinical and Experimental Neuropsychology. 1998 Oct 1;20(5):613-27.

47. Connor DF. Preschool attention deficit hyperactivity disorder: a review of prevalence, diagnosis, neurobiology, and stimulant treatment. Journal of Developmental & Behavioral Pediatrics. 2002 Feb 1;23:S1-9.

48. Greenhill LL, Posner K, Vaughan BS, Kratochvil CJ. Attention deficit hyperactivity disorder in preschool children. Child and Adolescent Psychiatric Clinics of North America. 2008 Apr 1;17(2):347-66.

49. Posner K, Melvin GA, Murray DW, Gugga SS, Fisher P, Skrobala A, Cunningham C, Vitiello B, Abikoff HB, Ghuman JK, Kollins S. Clinical presentation of attention-deficit/hyperactivity disorder in preschool children: The preschoolers with attention-deficit/hyperactivity treatment study (PATS). Journal of child and adolescent psychopharmacology. 2007 Oct 1;17(5):547-62.

50. Lahey BB, Pelham WE, Loney J, Lee SS, Willcutt E. Instability of the DSM-IV subtypes of ADHD from preschool through elementary school. Archives of general psychiatry. 2005 Aug 1;62(8):896-902.

51. Smidts DP, Oosterlaan J. How common are symptoms of ADHD in typically developing preschoolers? A study on prevalence rates and prenatal/demographic risk factors. Cortex. 2007 Jan 1;43(6):710-7.

52. Fabiano GA, Pelham Jr WE, Coles EK, Gnagy EM, Chronis-Tuscano A, O'Connor BC. A meta-analysis of behavioral treatments for attention-deficit/hyperactivity disorder. Clinical psychology review. 2009 Mar 1;29(2):129-40.

53. Evans SW, Owens JS, Bunford N. Evidence-based psychosocial treatments for children and adolescents with attention-deficit/hyperactivity disorder. Journal of Clinical Child & Adolescent Psychology. 2014 Jul 1;43(4):527-51.

54. Zametkin AJ, Ernst M. Problems in the management of attention-deficit–hyperactivity disorder. New England Journal of Medicine. 1999 Jan 7;340(1):40-6.

55. Pelham Jr WE, Wheeler T, Chronis A. Empirically supported psychosocial treatments for attention deficit hyperactivity disorder. Journal of clinical child psychology. 1998 Jun 1;27(2):190-205.

56. Elia J, Ambrosini PJ, Rapoport JL. Treatment of attention-deficit–hyperactivity disorder. New England Journal of Medicine. 1999 Mar 11;340(10):780-8.

57. Robison LM, Sclar DA, Skaer TL, Galin RS. National trends in the prevalence of attention-deficit/hyperactivity disorder and the prescribing of methylphenidate among school-age children: 1990-1995. Clinical pediatrics. 1999 May;38(4):209-17.

58. Jensen PS, Bhatara VS, Vitiello B, Hoagwood K, Feil M, Burke LB. Psychoactive medication prescribing practices for US children: gaps between research and clinical practice. Journal of the American Academy of Child & Adolescent Psychiatry. 1999 May 1;38(5):557-65.

59. Spencer T, Biederman J, Wilens T, Harding M, O'DONNELL DE, Griffin S. Pharmacotherapy of attention-deficit hyperactivity disorder across the life cycle. Journal of the American Academy of Child & Adolescent Psychiatry. 1996 Apr 1;35(4):409-32.

60. Goldman LS, Genel M, Bezman RJ, Slanetz PJ. Diagnosis and treatment of attention-deficit/hyperactivity disorder in children and adolescents. Jama. 1998 Apr 8;279(14):1100-7.

61. Jensen PS, Kettle L, Roper MT, Sloan MT, Dulcan MK, Hoven C, Bird HR, Bauermeister JJ, Payne JD. Are stimulants overprescribed? Treatment of ADHD in four US communities. Journal of the American Academy of Child & Adolescent Psychiatry. 1999 Jul 1;38(7):797-804.

62. Dulcan M. Practice parameters for the assessment and treatment of children, adolescents, and adults with attention-deficit/hyperactivity disorder. Journal of the American Academy of Child & Adolescent Psychiatry. 1997 Oct 1;36(10):85S-121S.

63. Faraone SV, Buitelaar J. Comparing the efficacy of stimulants for ADHD in children and adolescents using meta-analysis. European child & adolescent psychiatry. 2010 Apr;19:353-64.

64. Cyr M, Brown CS. Current drug therapy recommendations for the treatment of attention deficit hyperactivity disorder. Drugs. 1998 Aug;56(2):215-23.

65. Riddle MA, Nelson JC, Kleinman CS, Rasmusson A, Leckman JF, King RA, Cohen DJ. Sudden death in children receiving Norpramin®: A review of three reported cases and commentary. Journal of the American Academy of Child & Adolescent Psychiatry. 1991 Jan 1;30(1):104-8.

66. Riddle MA, Geller B, Ryan N. Another sudden death in a child treated with desipramine. Journal of the American Academy of Child & Adolescent Psychiatry. 1993 Jul 1;32(4):792-7.

67. Varley CK, McClellan JO. Case study: two additional sudden deaths with tricyclic antidepressants. Journal of the American Academy of Child & Adolescent Psychiatry. 1997 Mar 1;36(3):390-4.

68. Popper CW. Antidepressants in the treatment of attention-deficit/hyperactivity disorder. Journal of Clinical Psychiatry. 1997 Jan 1;58(14):14-31.

69. Barrickman L, Noyes R, Kuperman S, Schumacher E, Verda M. Treatment of ADHD with fluoxetine: a preliminary trial. Journal of the American Academy of Child & Adolescent Psychiatry. 1991 Sep 1;30(5):762-7.

70. Pliszka SR, Greenhill LL, Crismon ML, Sedillo A, Carlson C, Conners CK, McCRACKEN JT, Swanson JM, Hughes CW, Llana ME, Lopez M. The Texas children's medication algorithm project: Report of the Texas consensus conference panel on medication treatment of childhood attention-deficit/hyperactivity disorder. Part I. Journal of the American Academy of Child & Adolescent Psychiatry. 2000 Jul 1;39(7):908-19.

71. Wilens TE, Spencer TJ. Combining methylphenidate and clonidine: a clinically sound medication option. Journal of the American Academy of Child & Adolescent Psychiatry. 1999 May.
72. Hunt RD, Arnsten AF, Asbell MD. An open trial of guanfacine in the treatment of attention-deficit hyperactivity disorder. Journal of the American Academy of Child & Adolescent Psychiatry. 1995 Jan 1;34(1):50-4.
73. Ruggiero S, Clavenna A, Reale L, Capuano A, Rossi F, Bonati M. Guanfacine for attention deficit and hyperactivity disorder in pediatrics: a systematic review and meta-analysis. European Neuropsychopharmacology. 2014 Oct 1;24(10):1578-90.
74. Kean JD, Downey LA, Stough C. A systematic review of the Ayurvedic medicinal herb *Bacopa monnieri* in child and adolescent populations. *J Ethnopharmacol.* 2016;193:112–7.